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a b s t r a c t
Cardiomyopathies are myocardial disorders that are not explained by abnormal loading
conditions and coronary artery disease. They are classiﬁed into a number of morphological
and functional phenotypes that can be caused by genetic and non-genetic mechanisms. The
dominant themes in papers published in 2012–2013 are similar to those reported in Almanac
2011, namely, the use (and interpretation) of genetic testing, development and application of
novel non-invasive imaging techniques and use of serum biomarkers for diagnosis and
prognosis. An important innovation since the last Almanac is the development of more
sophisticated models for predicting adverse clinical events.
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Cardiomyopathies are myocardial disorders that are not
explained by abnormal loading conditions and coronary artery
disease. They are classiﬁed into a number of morphological
and functional phenotypes that can be caused by genetic and
non-genetic mechanisms. The dominant themes in papers
published in 2012–2013 are similar to those reported in
Almanac 2011, namely, the use (and interpretation) of genetic
testing, development and application of novel non-invasive
imaging techniques and use of serum biomarkers for diagnosis
and prognosis. An important innovation since the last
Almanac is the development of more sophisticated models
for predicting adverse clinical events.
Hypertrophic cardiomyopathy
Cardiac imaging and circulating biomarkers
Hypertrophic cardiomyopathy (HCM) occurs in one in every
500 adults and in most individuals is inherited as an
autosomal dominant trait caused by mutations in cardiac
sarcomere protein genes and is associated with an increased
risk of sudden cardiac death (SCD), progressive ventricular
dysfunction and stroke (Fig. 1) [1–3]. Diagnostic tools such as
ECG and echocardiography remain fundamental to diagnosis
and treatment of HCM but cardiac MRI (CMR) improves
diagnostic accuracy and provides additional phenotypic
information in patients with established disease (Fig. 2)
[4–7]. For example, in one study, CMR identiﬁed hypertrophy
in about 10% of sarcomere mutation carriers thought to have
normal wall thickness by echocardiography [8]. Novel CMR
sequences, such as T1 mapping, provide quantitative
estimates of the myocardial extracellular volume (ECV) (and
therefore a surrogate measure of interstitial ﬁbrosis) [5] and, in
one study, an increase in ECV was reported in individuals with
sarcomere mutations but without LV hypertrophy [9]. These
ﬁndings suggest that selective use of CMR may be helpful in
family screening, particularly when they are other features
consistent with HCM, such as ECG abnormalities.
The clinical relevance of myocardial scar inferred from
abnormal gadolinium enhanced CMR is a recurring subject in
the literature. Available data support a relation among late
gadolinium enhancement (LGE), representing macroscopic
focal myocardial scar, and cardiovascular mortality, heart
failure death and all-cause mortality but show only a trend
towards an increased risk of SCD [10,11]. ECV measured by
CMR correlates with concentrations of both N-terminal pro-
brain natriuretic peptide and serum biomarkers of collagen
synthesis providing further evidence that myocardial ﬁbrosis
is important early in disease pathogenesis [9].Numerous papers have investigated biomarkers as a tool
for diagnosis and prognosis and have shown predicting
poor outcome in patients with heart failure [12]. In a study
of 772 patients with HCM, brain natriuretic peptide (BNP) was
an independent predictor of morbidity in mortality [13]. In
another study of 183 stable outpatients, plasma NT-proBNP
was a predictor of heart failure-related events [14] and was a
predictor of heart failure and transplant-related death but not
sudden death or inappropriate implantable cardioverter
deﬁbrillator (ICD) shocks [15]. A further study of 183 patients
reports elevated serum concentrations of high-sensitivity
cardiac troponin T to predict adverse outcomes in HCM
[16].
Treatment strategies
Current management of individuals with HCM focuses on
prevention of SCD and stroke, relief of drug-refractory
symptoms associated with LV outﬂow tract obstruction
(LVOTO), and palliation of limiting symptoms caused by
systolic or diastolic dysfunction. There have been few
developments in therapy since the last Almanac, but early
prophylactic b-blocker therapy in physically active patients
(NYHA 1 and 2) with provokable LVOTO has been shown to be
effective in reducing outﬂow gradients during physiological
exercise [17]. Another study has conﬁrmed the additive beneﬁt
of disopyramide in therapy of symptomatic patients with
obstruction resistant to initial therapy with b-blocker or
verapamil [18].
Invasive treatment of LVOTO is recommended for patients
with drug-refractory symptoms. Several studies have provided
new data on septal alcohol ablation (SAA) and LV septal
myectomy. Over a follow-up of 5.7 years, survival following
SAA in 177 patients was similar to that of patients treated with
septal myectomy and a matched control population. Pace-
makers were required in 20.3% in patients who underwent SAA
compared with 2.3% in the surgical cohort in the 30 days
following the procedure [19]. Similar results following SAA
were reported in a study of 470 patients [20] in whom 10-year
survival (all-cause death rate 1.2%) was 88% compared with
84% in a matched normal population (Fig. 3); the same authors
also report a reduction in SCD risk factors. In a study of
239 patients, septal myectomy was associated with a reduc-
tion in syncope and increased survival [21]. Another study
reports a cumulative incidence of HCM-related death of 3.3% at
5 years [22]. Finally, in 699 patients age and persistent atrial
ﬁbrillation were reported to be predictors of poorer outcome in
patients undergoing surgical myectomy [23].
New data have re-examined the efﬁcacy of dual chamber
pacing for refractory symptomatic LVOTO [24,25]. In a recent
Cochrane review, it was noted that all data derive from small
studies and that the few randomised trials [26,27] concentrate
on physiological outcome measures rather than hard clinical
Fig. 1 – Prevalence of atrial fibrillation and thromboembolism.
Guttmann et al [3] investigated a population of 7381 patients
with hypertrophic cardiomyopathy. A meta-analysis reveals
an overall prevalence of atrial fibrillation of 22.45%. The
forest plot from random effect meta-analysis shows study-
specific prevalence and the pooled (overall) prevalence of AF.
The heterogeneity between the study was estimated as
I2=78.9% (p<0.001). The overall prevalence of
thromboembolism is 27.09%. The forest plot from random
effect meta-analysis shows study-specific prevalence and
the pooled (overall) prevalence of thromboembolism in
patients with hypertrophic cardiomyopathy and atrial
fibrillation. The heterogeneity between the studies was
estimated as I2=61.4% (p<0.01).
Fig. 2 – Extracellular volume (ECV) in health and disease:
inter-group comparison showing disease-specific
variability. Sado et al [5] measured and assessed the
significance of myocardial ECV as a clinical biomarker in
health and a number of cardiac diseases. The data are
presented as meanW2 SEs.
Fig. 3 – Jensen et al [20] investigated overall survival (solid
black) and survival free of sudden cardiac death (SCD)
including appropriate implantable cardioverter defibrillator
discharge and aborted cardiac arrest (dashed black) after
alcohol septal ablation in 470 patients with hypertrophic
obstructive cardiomyopathy (follow-up 8.4W4 years).
Comparison is made with the overall survival of an age-
and sex-matched background population (grey). N
indicates number of patients at risk at the indicated time.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 8 – e 3 8e30endpoints. As a result, they recommend large and high quality
trials [28].
Prevention of SCD
A recent systematic review and meta-analysis of 27 studies
reported an appropriate ICD intervention rate of 3.3% peryear with an inappropriate shock rate of 4.8% per annum [29]
but in a single centre study of 334 patients with HCM, patients
still had a signiﬁcant cardiovascular mortality (predominantly
heart failure) and experienced frequent inappropriate shocks
and implant complications. These ﬁndings suggest that new
strategies are required to improve patient selection for ICDs
Fig. 4 – O'Mahony et al [30] evaluated 334 patients with hypertrophic cardiomyopathy (HCM) at risk of sudden death treated
with ICD. They conclude that HCM patients with an ICD have a significant cardiovascular mortality and are exposed to
frequent inappropriate shocks and complications. Kaplan–Meier curves for survival free from cardiovascular mortality end-
point (A) stratified according to device implantation for primary or secondary prevention, appropriate shocks (B) stratified
according to impaired systolic function, inappropriate shocks (C), implant complications (D) stratified according to device
complexity, implant complications in patients with single-or dual-chamber ICDs (cardiac resynchronisation therapy patients
excluded) (E), and implantable cardioverter defibrillator-related adverse events (inappropriate shocks or implant
complications) for the whole cohort (F).
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 8 – e 3 8 e31and prevent disease progression in those who receive a device
(Fig. 4) [30].
Contemporary risk assessment relies on a small number of
readily obtained clinical risk markers to predict SCD and is
widely used to guide implantation of ICDs [31,32], but recent
evidence suggests that this approach distinguishes high and
low risk individuals with only limited predictive power [33].
Additionally, several recently proposed prognostic factors
(such as LVOTO and age) are not included in the assessment
[10,32,34]. Recent data have also reinforced the importance of
age in risk stratiﬁcation. In a study of 428 patients above the
age of 60 years, 3.7% died secondary to HCM-related causesincluding embolic stroke, heart failure and transplantation.
SCD events occurred in ﬁve patients (1.2% or 0.2% per year).
The authors conclude that patients with HCM surviving to an
age above 60 are at low risk for HCM-related mortality and
sudden death [35].
It has been suggested that conventional risk prediction
algorithms do not apply to paediatric populations [36]. In a
paediatric cohort, judged clinically to be at high risk,
appropriate ICD shocks were delivered in 19% of 224 patients
followed for 4.33.3 years with an annual rate of 4.5% per
year. However, as device-related complications occurred
in 41% (especially lead complications and inappropriate
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 8 – e 3 8e32shocks) of patients [37], more data in paediatric cohorts are
required to determine the net beneﬁt of ICD therapy in the
young.
Cost efﬁcacy of family screening
Economic models of genetic testing for the evaluation of
families with HCM report that genetic testing is cost-effective
when combined with conventional clinical screening [38,39].
These models are based on the assumption that risk-
algorithms from high risk populations can be applied to low
risk populations detected through screening and that preven-
tive treatment with ICDs is effective. Additionally, these
models and many clinical screening programmes assume a
relatively high disease penetrance.
In a study comparing clinical screening and predictive
genetic testing in children and adolescents, 90 patients with
HCM and 361 relatives were followed for 12 years [40]. In a group
of 12 young mutation carriers without LV hypertrophy, at initial
assessment only two developed HCM during the period of the
study suggesting an unexpectedly low penetrance during
adolescence, a period conventionally associated with the
greatest rates of phenotype conversion. Importantly, the two
cases were diagnosed at the ages of 26 and 28 years,
emphasising the importance of screening beyond adolescence.
Conventional clinical screening strategies and the clinical role
of genetic testing including its cost-effectiveness will need to be
re-evaluated if larger studies show similar ﬁndings.
Preliminary evidence suggests that long term clinical and
genetic screening in children and adults is not associated with
major adverse psychological consequences [40]. The effect on
social and professional aspects has to be evaluated.
Genotype–phenotype relations
The establishment of clinically useful relations between
genotype and phenotype remains elusive in HCM. A recent
systematic review reported a higher prevalence of family
history of HCM and SCD, younger age at presentation, and
greater maximal LV in individuals with a sarcomere gene
mutation but no difference was reported in clinical character-
istics when comparing MYBPC3 and MYH7 mutations.
However, these data were limited by the inconsistency of
study design and the small size of many study cohorts [41].
In addition to traditional clinical expression studies, several
groups are using human induced pluripotent stem cell (iPSC)-
derived cardiac myocytes to study disease pathogenesis.
Immunostaining and patch clamping were used to identify
disease-speciﬁc phenotypes and differences in cardiac drug
toxicity between different cell-lines [42]. The same group used a
similar technique to demonstrate that restoration of calcium
homeostasis prevented the development of myocyte hypertro-
phy and electrophysiological abnormalities in pluripotent stem
cell-derived cardiomyocytes carrying a MYH7 mutation [43].
Arrhythmogenic right ventricular cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is
clinically characterised by arrhythmia, SCD and progressiveheart failure. Cardiomyocyte loss and replacement by ﬁbrous
or ﬁbrofatty tissue are histological hallmarks of the disease.
ARVC is caused by mutations in genes that encode constitu-
ents of the intercalated disc of cardiomyocytes in a large
proportion of patients [44]. Diagnosis requires integration of
data from family members, genetic testing, electrocardiogra-
phy and imaging techniques [45]. SCD and treatment of
symptomatic arrhythmia and heart failure are the major
management challenges.
Clinical diagnosis of ARVC
While evidence suggests that recent modiﬁcation of pro-
posed diagnostic criteria has improved diagnostic sensitivity
and speciﬁcity [46,47], there is a concern that they remain
too sensitive in particular scenarios, most notably athletes
and in people of black African ethnic origin, as many
structural and electrographic changes considered normal in
these groups are also minor diagnostic criteria for ARVC
[48,49].
Novel methods to detect early phenotypic expression in
ARVC have included immunohistochemical and electrophys-
iological approaches. A report suggested that immunohisto-
chemical demonstration of reduced plakoglobin signal in
myocardial biopsies has a sensitivity of 85% and speciﬁcity
of 57% for ARVC. The authors suggested the test could be
used in diagnosis [50], but the performance of the assay in
prephenotypic cases—where it is most valuable—has not
been assessed. Another group of investigators observed a
marked reduction in immunoreactive signal for plakoglobin
at cardiac myocyte junctions in patients with sarcoidosis and
giant cell myocarditis [51]. This suggests new disease
mechanisms involving desmosomal proteins in granuloma-
tous myocarditis and implicates cytokines in dislocation of
plakoglobin from desmosomes and in the development of
arrhythmia in ARVC.
A recent study reported abnormalities in conduction-
repolarisation kinetics detected by invasive electrophysiologi-
cal testing in 10 unrelated individuals and a mouse model with
desmoplakin mutations [52]. Notably, these abnormalities
preceded overt structural changes.
Aetiology
ARVC is inherited as an autosomal dominant trait in up to 50%
of cases [53] and incomplete penetrance (including age-
dependent penetrance) and variable clinical expression are
the norm. Over the last year, the genetic heterogeneity of ARVC
has been underlined by reports of novel mutations in the genes
for phospholamban, desmocollin-2, TMEM43, CTNNA3 (a T
catenin) and a gene deletion in plakophilin-2 [54–60]. Addi-
tionally, mutations in genes hitherto associated with other
cardiomyopathies have been reported in families and studies
of individuals with ARVC. These include the non-desmosomal
protein lamin A/C [61]. The role of other genetic and epigenetic
mechanisms on disease expression remains an area of active
research [62].
Advances in genetics may improve the speciﬁcity of
diagnostic algorithms in the future but data show that there
are many challenges in the interpretation ofsequence data. In a
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 8 – e 3 8 e33study of 427 controls and 93 ARVC probands [63], exons and
splice acceptor/donor sites of PKP2, DSP, DSG2, DSC2 and
TMEM43 were sequenced. Likely pathogenic mutations were
identiﬁed in 58% of the ARVC cases, but were also found in 16%
of the controls. The majority (43%) of the candidate mutations in
cases were radical (ie, splice site, nonsense, inframe and frame-
shift insertions and deletions) compared with only 0.5% of
controls but the frequency of missense mutations was similar in
cases (21%) and controls (16%). Other important ﬁndings were a
higher frequency of candidate variants, in particular missense,
in non-Caucasian versus Caucasian controls (19.44% vs 5.83%)
and similar numbers of variants in the DSP, DSC2 and TMEM43
genes in the ARVC and control groups. These ﬁndings illustrate
the conservative approach that must be followed when
interpreting genetic variants in ARVC.
The use of iPSCs as a model of ARVC was recently described
[64]. Heterozygous mutant plakophilin-2 iPSC cardiomyocytes
demonstrated exaggerated lipogenesis and apoptosis and
calcium-handling deﬁcits were detected in homozygous
mutants. Greater understanding of these phenomena might
lead to development of novel disease-modifying therapeutic
strategies in the future.
Management strategies
Once ARVC has been diagnosed, management should
include an assessment of SCD risk, indications for drug
therapy and need for lifestyle changes. Although antiar-
rhythmic drugs such amiodarone and sotalol are frequently
prescribed to decrease arrhythmic burden [44], there is little
evidence that these improve survival or alter the natural
history of disease. The same is true for treatment of any
associated LV systolic impairment with ACE inhibitors and b-
blockers.
Physical exercise and competitive sport have been reported
to increase the risk of sudden death [65,66] and are
consequently not recommended [67,68]. More recently, exer-
cise has been associated with increased disease penetrance
and arrhythmic risk in individuals with a desmosomal
mutation. Task force criteria were more likely to be met at
follow-up and symptoms developed at a younger age in
56 endurance athletes carrying a mutation compared with
more sedentary mutation carriers. These athletes also had a
decreased lifetime survival free from ventricular tachycardia
(VT)/ventricular ﬁbrillation and heart failure [69]. These
ﬁndings correlate with preclinical observations in murine
model of ARVC with plakophilin gene defects [70].
Catheter ablation to treat recurrent VT in ARVC has been
associated with high recurrence rates [71,72] but a recent
multicentre study with focus on newer ablation strategies
assessed recurrence of VT following radiofrequency ablation
and effect on burden of VT. The authors report a signiﬁcant
reduction in VT burden and longer survival free of VT following
epicardial ablation compared with an endocardial procedure.
However, recurrence rates remain considerable with an overall
freedom from VT of 47% at 1 year [73]. These data suggest that
catheter ablation may be helpful in a subgroup of patients with
incessant or frequent VT refractory to medical therapy. Some
data suggest that VT attributable to localised disease is a
further potential indication [74].Prevention of sudden death
Current AHA/ACC/ESC guidelines for the management of
patients with ventricular arrhythmias and the prevention of
SCD recommend ICD implantation in patients with ARVC who
have documented sustained VT or ventricular ﬁbrillation and
are receiving optimal medical treatment [75]. A recent
literature review investigating outcomes and complications
of ICD implantation in ARVC included 610 patients. During the
3.8-year follow-up, the authors reports appropriate ICD
interventions at a rate of 9.5% per year with inappropriate
interventions (3.7%) and complications including lead
malfunction, displacement and infection (20.3% rate of any
complication) [76]. Once again, this underlines the need for
appropriate risk stratiﬁcation to minimise morbidity sec-
ondary to ICD-related complications. It is important to point
out that the patients analysed in this review received an ICD
for primary or secondary prevention. This could at least
partially account for the high rate of appropriate interven-
tions.
The incremental value and role of CMR in risk stratiﬁca-
tion were investigated in 69 patients with ARVC-associated
mutations (83% with PKP-2 mutations) without prior sus-
tained VT [77]. Electrical abnormalities were found in 61% of
patients of whom 48% also had an abnormal CMR (deﬁned as
presence of at least a minor task force criterion). Only a
single patient (4%) without electrical abnormalities had an
abnormal heart on imaging at baseline. Over a period of 5.8
4.4 years, episodes of sustained VT only occurred in
patients with ECG and CMR abnormalities. The authors
concluded that among mutation carriers the presence of
both electrical and CMR abnormalities identiﬁed high risk
patients. A similar study on prognosis in patients under
evaluation for ARVC reports a positive predictive value of an
abnormal CMR in 369 patients who fulﬁlled at least one
minor or major diagnostic criterion for ARVC. The negative
predictive value of a normal CMR was 98.8% over a follow-up
of 4.31.5 years [78].
The search for biomarkers that allow early diagnosis and
risk stratiﬁcation is an active area of research. For example,
low serum concentrations of Bridging integrator 1, a mem-
brane-associated protein, were associated with ventricular
arrhythmias and reduced functional status in a small cohort of
24 patients with ARVC [79].
A novel strategy to risk prediction in ARVC-associated
desmosomal mutation carriers proposes the use of pedigree
evaluation, ECG and Holter information [80]. Phenotypic
characteristics were used in stratifying the risk of sustained
VT. The investigators included 215 patients over a mean
follow-up of 7 years. Patients were risk stratiﬁed according to
repolarisation and depolarisation abnormalities on ECG.
Event-free survival at 5 years was 33% in the high risk group
versus 97% in the low risk group.
Dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is one of the commonest heart
muscle diseases in developed countries. It is deﬁned as systolic
impairment and LV dilatation in the absence of previous
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 8 – e 3 8e34myocardial infarction. Research highlighting the importance
of genetics in the aetiology of inherited and apparently
acquired forms of DCM has been a prominent feature over
the last few years. Standard symptomatic and prognostic heart
failure treatments are the mainstay of patient management
but more attention has been paid recently to the importance of
aetiology in guiding the approach to management.
Genetic subtypes of DCM
A number of studies have examined the natural history of
DCM caused by mutations in the lamin A/C gene (LMNA). This
is associated with conduction disease, atrial arrhythmias,
heart failure and sudden death and should be suspected when
DCM is accompanied by elevated serum creatine kinase,
conduction disease or frequent arrhythmias. In these
patients, evidence suggests an ICD should be considered at
a much lower threshold than in other cases of DCM [81–83]. A
multicentre cohort of 269 patients with LMNA mutation
identiﬁed non-sustained VT, LVEF <45%, male gender and
non-missense mutations as risk factors for malignant
ventricular arrhythmias [84]. Some authorities suggest ICD
implantation should be considered following even mild
cardiac expression.
A recent report suggests that titin (TTN) mutations are a
common cause of DCM [85]. TTN mutations have long been
considered candidate causes of cardiomyopathy, but the size
of the gene and the presence of many allelic variants have
made it difﬁcult to study [86–89]. To overcome some of these
difﬁculties, Herman and colleagues [85] used next generation
sequencing to analyse genomic TTN sequence for mutations
that altered full-length cDNA (truncating mutations) in 792
subjects (312 DCM, 231 HCM and 249 controls). Truncating
TTN mutations were found more frequently in DCM (27%)
than in HCM (1%) or controls (3%). TTN mutations cosegre-
gated with DCM in families with penetrant disease, but were
also found in 18% of apparently sporadic cases. TTN
sequencing is therefore likely to have a prominent role in
the genetic evaluation of DCM patients in order to facilitate
prephenotypic diagnosis, but the high frequency in controls
and sporadic cases suggests that the majority of TTN mutants
may yet prove to be susceptibility rather than causative
factors.
The importance of epigenetic factors (ie, processes that
alter gene activation without changing DNA sequence) has
also been highlighted since 2011. In a study comparing
genome-wide cardiac DNA methylation in patients with
idiopathic DCM and controls, Haas et al detected differences
in the methylation of genes implicated in heart failure
pathways. These were associated with differences in mRNA
expression, a ﬁnding further strengthened by studies in zebra
ﬁsh [90]. Epigenetics research is particularly advanced in
cancer biology, contributing to potential therapeutic/diagnos-
tic biomarker and therapeutic targets [91–93]. Its potential in
cardiovascular genetics is yet to be realised.
Genetic predisposition to inﬂammatory myocardial dam-
age is also emerging as an important theme [94]. The
Coxsackie virus, a common cause of myocarditis, causes
proteolysis of dystrophin in infected cardiomyocytes [95–97].
Genetic defects of the dystrophin–glycoprotein complex,associated with muscular dystrophy, frequently cause a
DCM where CMR ﬁndings are often indistinguishable from
myocarditis [98]. In another study, the presence of variants in
Toll-like receptors which play a key role in the innate immune
response were associated with poorer cardiac function in 158
patients [99]. Finally, Meder et al [100] present data associating
the locus containing major histocompatibility genes (MHC I
and II) with DCM. The authors identiﬁed multiple single
nucleotide polymorphisms on chromosome 6p21. A speciﬁc
locus was identiﬁed and an association was found with closely
located genes encoding class I and class II major histocom-
patibility complex heavy chain receptors.
Prediction of outcomes in DCM
As in other cardiomyopathies, the role of CMR in predicting
outcomes is an active area of study in DCM. Recent evidence
suggests that the presence of midwall LGE identiﬁes a DCM
cohort at increased mortality risk. During a median follow-up
period of just over 5 years, 27% of 142 DCM with LGE patients
died compared with 11% of 330 DCM patients without LGE
[101]. The pathophysiological basis of this difference is
unclear.
Data describing the diagnostic and prognostic utility of CMR
surrogate for other tissue abnormalities, such as oedema,
diffuse ﬁbrosis or myocyte disarray, are expected in the near
future.
Some of the most important data since 2011 have been in
children with DCM. In a paediatric registry population of 1803
patients, a 5-year incidence rate of 29% for heart transplanta-
tion, 12.1% non-SCD and 2.4% for SCD are quoted. A risk
stratiﬁcation model for SCD based on echocardiography data
had a sensitivity of 86% and 57% speciﬁcity. Signiﬁcant factors
were LV dilatation, age at diagnosis and posterior wall
thinning [102].
Another study investigating 175 paediatric patients with
DCM reports death or transplantation in 26% within 1 year of
diagnosis with a survival free of death or transplant of 56% 20
years after diagnosis. An increased risk for death or transplant
was associated with the age at diagnosis, presence of familial
cardiomyopathy and lower baseline LV fractional shortening
[103].
Advances in treatment
Stem cell therapy has been a major topic over the course of the
last few years. A 5-year follow-up randomised controlled study
of 110 patients with DCM shows improved LV function,
improved exercise tolerance and greater long term survival
in patients who underwent intracoronary stem cell transplan-
tation. Total mortality was 14% in the stem cell group versus
35% in the controls with rates of pump failure of 5% versus
18%. There was no difference in rates of sudden death [104]. A
systematic review on 29 preclinical and 15 clinical studies
scrutinised stem cell therapy as a treatment for DCM. The
majority of studies showed a modest improvement of LVEF
after cell therapy during follow-up. Due to the large heteroge-
neity in criteria for inclusion, procedure and outcome
measure, the need for randomised controlled trials was
stressed [105].
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 8 – e 3 8 e35Effect of exercise has been evaluated in patients with DCM
following an 8-week period of short term exercise. Signiﬁcant
improvement in cardiac function at rest and following exercise
was reported with sedentary patients having the greatest
improvement [106].
The importance of immune activation is another focus for
therapy in DCM. Atorvastatin in a small dose reduced the
levels of inﬂammatory cytokines (IL-6, TNF a), uric acid and N-
terminal pro-brain natriuretic peptide in a small cohort of
patients with DCM [107].
Overall evidence suggests improving survival in patients
with idiopathic DCM. A study of 603 patients over three
decades gives evidence for the impact of clinical guidelines on
morbidity and mortality. Patients were subdivided in four
enrolment periods and a 42% risk reduction per enrolment
interval with regard to heart failure-related mortality and
sudden death was reported [108].
Summary
Cardiomyopathies continue to be an area of intense interest in
the literature. While the spectrum of disease is considerable
and continues to expand, the themes are very similar between
cardiomyopathy subtypes, with great emphasis on accurate
diagnosis, disease stratiﬁcation and aetiology driven therapy.
Advances in these areas will depend on discovery science and
the application of omic technologies, but the greatest insights
are likely to emerge from large scale multicentre collabora-
tions. All the evidence suggests that the next few years will be
one of considerable advance.
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